What Is Takeda Pharmaceutical Company L (TAK) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Takeda Pharmaceutical Company L's intrinsic value is estimated at $25.15, suggesting a +52.6% average upside from the current price of $16.49. While 7 models see room for appreciation, model agreement is not unanimous as 4 models flag potential overvaluation. Model dispersion is worth noting: Bayesian DCF targets $72.51 (+339.8%), versus Regime Cross at $4.58 (-72.2%). This +412.1% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About TAK?
12 of 13 models are currently active for TAK. Of these, 7 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates TAK's intrinsic value at $72.51, implying +339.8% upside from the current price. See which stocks rank higher →
How Does TAK Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, TAK ranks #41 by Quality of Company score. CirclFi's QOC score of 7.7/10 evaluates 32 fundamental signals. A score of 7.7 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Takeda Pharmaceutical Company L's positioning within the Pharmaceutical Preparations segment means that FDA approval probability plays an outsized role in fundamental analysis. The sector's unique characteristics — including regulatory pathway clarity — shape both the opportunity set and risk profile.
Is TAK a Value Trap?
CirclFi's Value Trap algorithm assigns TAK a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Takeda Pharmaceutical Company L. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Takeda Pharmaceutical Company L scores 7.7 out of 10 on our 32-signal quality assessment, a strong rating that demonstrates strong fundamentals across the majority of our quality signals. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +412.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every TAK valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across TAK's 12 active models, average confidence is 40%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad